Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2016 1
2019 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Ann, 5Bjour
Page 1
Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy.
Barba-Romero MÁ, Serena J, Puig JM, Valverde C V, Climent V, Herrero JA, Huertas R, Torra R. Barba-Romero MÁ, et al. Med Clin (Barc). 2019 Jul 19;153(2):47-55. doi: 10.1016/j.medcli.2018.10.039. Epub 2019 Jan 15. Med Clin (Barc). 2019. PMID: 30658922 English, Spanish.
Assessments on symptomatology and severity were collected using several clinical questionnaires. Additionally, clinical information and lab tests were obtained from clinical records. RESULTS: Thirty-three women with a mean age of 45.616.2 years were studied. Symptom onset …
Assessments on symptomatology and severity were collected using several clinical questionnaires. Additionally, clinical information and l …
Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N, Bawa S, Ali MR, Kalra S, Kumar R, Zeya B, Rizvi MA, Partap S, Husain A. Shalmali N, et al. Anticancer Agents Med Chem. 2022;22(11):2166-2180. doi: 10.2174/1871520621666211118102139. Anticancer Agents Med Chem. 2022. PMID: 34792005
Molecular docking was performed to explore the binding and interactions with the active sites of the VEGFR-2 receptor (PDB Id: 3VHE). Derivatives 5a, 5b, 5c, 5d, 5g, 5h, and 5m were assessed for in vitro inhibition potency against Human VEGFR-2 using ELISA (Enzyme- Linked …
Molecular docking was performed to explore the binding and interactions with the active sites of the VEGFR-2 receptor (PDB Id: 3VHE). Deriva …
Early Clinical and Electrophysiological Brain Dysfunction Is Associated With ICU Outcomes in COVID-19 Critically Ill Patients With Acute Respiratory Distress Syndrome: A Prospective Bicentric Observational Study.
Benghanem S, Cariou A, Diehl JL, Marchi A, Charpentier J, Augy JL, Hauw-Berlemont C, Gavaret M, Pène F, Mira JP, Sharshar T, Hermann B. Benghanem S, et al. Crit Care Med. 2022 Jul 1;50(7):1103-1115. doi: 10.1097/CCM.0000000000005491. Epub 2022 Feb 9. Crit Care Med. 2022. PMID: 35135966 Free PMC article.
Early nonreactive EEG was associated with lower day-28 ventilator-free days (0 vs 16; p = 0.025), coma-free days (6 vs 22; p = 0.006), delirium-free days (0 vs 17; p = 0.006), and higher mortality (41% vs 11%; p = 0.027), whereas discontinuous background was associated wit …
Early nonreactive EEG was associated with lower day-28 ventilator-free days (0 vs 16; p = 0.025), coma-free days (6 vs 22; p = 0.006) …
Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia.
Nickler M, Schaffner D, Christ-Crain M, Ottiger M, Thomann R, Hoess C, Henzen C, Mueller B, Schuetz P. Nickler M, et al. Clin Chem Lab Med. 2016 Nov 1;54(11):1831-1846. doi: 10.1515/cclm-2016-0001. Clin Chem Lab Med. 2016. PMID: 27101551 Clinical Trial.
METHODS: Within this secondary analysis including 753 patients with a final inpatient diagnosis of CAP from a multicenter trial, we investigated associations between admission biomarker levels and decline in QoL assessed by the EQ-5D health questionnaire from admission to …
METHODS: Within this secondary analysis including 753 patients with a final inpatient diagnosis of CAP from a multicenter trial, we investig …
Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus.
Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Nojima J, et al. Br J Haematol. 2001 Sep;114(3):647-54. doi: 10.1046/j.1365-2141.2001.02950.x. Br J Haematol. 2001. PMID: 11552993 Free article.

Regarding IgG anti-prothrombin, the prevalence of VTE was significantly higher in group A (16/35 cases, 45.7%, P < 0.001, Fisher's exact probability test) than in the other groups (B, 2/30, 6.7%; C, 1/22, 4.5%; D, 1/37, 2.7%). With respect to IgM anti-prothrombin and Ig

…

Regarding IgG anti-prothrombin, the prevalence of VTE was significantly higher in group A (16/35 cases, 45.7%, P < 0.001, Fisher's exact

…